Effects of intranasal administration of synthetic (4-28)human atrial natriuretic peptide to normal volunteers.
The effects of intranasal administration of increasing doses of synthetic human natriuretic peptide (4-28 hANP) were studied in six healthy volunteers. The peptide was administered as a nasal spray at doses of 50, 100, 200, and 500 micrograms in ascending order at 48-h intervals. Vehicle was administered by the same route randomly between any two of the doses. Intranasal hANP administration had no effect on either blood pressure, heart rate (HR), or hematocrit. Diuresis did not change consistently, whereas natriuresis tended to rise with vehicle as well as with hANP administration. This was attributed to the infusion of isotonic saline during the experiment. There was no significant increase in plasma ANP levels after intranasal administration of any of the different doses. Thus, no evidence that the atrial natriuretic peptide tested (4-28 hANP) can cross the nasal mucosal barrier was found.
Delabays
A
A
Hypertension Division, University Hospital, Lausanne, Switzerland.
Porchet
M
M
Waeber
B
B
Nussberger
J
J
Brunner
H R
HR
D000281:Administration, Intranasal; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D010446:Peptide Fragments; C081681:atrial natriuretic factor (4-28); D009320:Atrial Natriuretic Factor